RESUMEN
We investigated dengue and chikungunya virus antibody seroprevalence in French Polynesia during 2014-2015. Dengue virus seroprevalence was ≈60% among schoolchildren and >83% among the general population; chikungunya virus seroprevalence was <3% before and 76% after Zika virus emergence (2013). Dengue virus herd immunity may affect Zika virus infection and pathogenesis.
Asunto(s)
Anticuerpos Antivirales/inmunología , Fiebre Chikungunya/epidemiología , Fiebre Chikungunya/inmunología , Virus Chikungunya/inmunología , Virus del Dengue/inmunología , Dengue/epidemiología , Dengue/inmunología , Adolescente , Adulto , Anticuerpos Neutralizantes/inmunología , Fiebre Chikungunya/historia , Niño , Preescolar , Dengue/historia , Historia del Siglo XXI , Humanos , Persona de Mediana Edad , Pruebas de Neutralización , Polinesia/epidemiología , Estudios Seroepidemiológicos , Adulto JovenRESUMEN
Ross River virus (RRV), spread by Aedes and Culex mosquitoes, is the most commonly transmitted arbovirus in Australia. A serosurvey of blood donors in French Polynesia during 2011-2013 suggested that RRV circulated without being detected. We report RRV circulation in French Polynesia based on further screening of blood samples collected during 2014-2015.
Asunto(s)
Aedes/virología , Infecciones por Alphavirus/epidemiología , Anticuerpos Antivirales/sangre , Culex/virología , Inmunoglobulina G/sangre , Insectos Vectores/virología , Virus del Río Ross/aislamiento & purificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Infecciones por Alphavirus/transmisión , Infecciones por Alphavirus/virología , Animales , Enfermedades Asintomáticas , Donantes de Sangre , Niño , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polinesia/epidemiología , Virus del Río Ross/inmunología , Estudios SeroepidemiológicosRESUMEN
During 2013-2014, French Polynesia experienced an outbreak of Zika virus infection. Serosurveys conducted at the end of the outbreak and 18 months later showed lower than expected disease prevalence rates (49%) and asymptomatic:symptomatic case ratios (1:1) in the general population but significantly different prevalence rates (66%) and asymptomatic:symptomatic ratios (1:2) in schoolchildren.
Asunto(s)
Brotes de Enfermedades , Estudios Seroepidemiológicos , Infección por el Virus Zika/epidemiología , Infección por el Virus Zika/virología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polinesia/epidemiología , Adulto Joven , Infección por el Virus Zika/sangreRESUMEN
Secrétariat de la surveillance dans la Polynésie française Santé alerter le public sur le virus, Zika, la fièvre de la dengue et ses complications causées par les moustiques Aedes.
Asunto(s)
Flavivirus , Dengue/epidemiología , Virus Chikungunya , Aedes/virología , Síndrome de Guillain-Barré/diagnósticoRESUMEN
BACKGROUND: Between October, 2013, and April, 2014, French Polynesia experienced the largest Zika virus outbreak ever described at that time. During the same period, an increase in Guillain-Barré syndrome was reported, suggesting a possible association between Zika virus and Guillain-Barré syndrome. We aimed to assess the role of Zika virus and dengue virus infection in developing Guillain-Barré syndrome. METHODS: In this case-control study, cases were patients with Guillain-Barré syndrome diagnosed at the Centre Hospitalier de Polynésie Française (Papeete, Tahiti, French Polynesia) during the outbreak period. Controls were age-matched, sex-matched, and residence-matched patients who presented at the hospital with a non-febrile illness (control group 1; n=98) and age-matched patients with acute Zika virus disease and no neurological symptoms (control group 2; n=70). Virological investigations included RT-PCR for Zika virus, and both microsphere immunofluorescent and seroneutralisation assays for Zika virus and dengue virus. Anti-glycolipid reactivity was studied in patients with Guillain-Barré syndrome using both ELISA and combinatorial microarrays. FINDINGS: 42 patients were diagnosed with Guillain-Barré syndrome during the study period. 41 (98%) patients with Guillain-Barré syndrome had anti-Zika virus IgM or IgG, and all (100%) had neutralising antibodies against Zika virus compared with 54 (56%) of 98 in control group 1 (p<0.0001). 39 (93%) patients with Guillain-Barré syndrome had Zika virus IgM and 37 (88%) had experienced a transient illness in a median of 6 days (IQR 4-10) before the onset of neurological symptoms, suggesting recent Zika virus infection. Patients with Guillain-Barré syndrome had electrophysiological findings compatible with acute motor axonal neuropathy (AMAN) type, and had rapid evolution of disease (median duration of the installation and plateau phases was 6 [IQR 4-9] and 4 days [3-10], respectively). 12 (29%) patients required respiratory assistance. No patients died. Anti-glycolipid antibody activity was found in 13 (31%) patients, and notably against GA1 in eight (19%) patients, by ELISA and 19 (46%) of 41 by glycoarray at admission. The typical AMAN-associated anti-ganglioside antibodies were rarely present. Past dengue virus history did not differ significantly between patients with Guillain-Barré syndrome and those in the two control groups (95%, 89%, and 83%, respectively). INTERPRETATION: This is the first study providing evidence for Zika virus infection causing Guillain-Barré syndrome. Because Zika virus is spreading rapidly across the Americas, at risk countries need to prepare for adequate intensive care beds capacity to manage patients with Guillain-Barré syndrome. FUNDING: Labex Integrative Biology of Emerging Infectious Diseases, EU 7th framework program PREDEMICS. and Wellcome Trust.